SUVENSuven Life Sciences Ltd.

₹203.5-2.82%

Market Cap

₹4,761.04 Cr

Stock P/E

-25.84

ROCE

-84.51%

ROE

-84.88%

Book Value

₹7.93

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Financially Stressed

Suven Life Sciences Ltd. shows significant weaknesses across all metrics compared to its peers, including negative revenue growth, margins, and returns. Meanwhile, companies like Sun Pharmaceutical Industries and Cipla demonstrate strong growth and profitability, indicating a stark differentiation in performance within the sector.

Key Points

• Suven Life Sciences has negative revenue growth (-13.63% YoY) and profitability metrics (PAT margin of -898.62%).
• Strong performers like Sun Pharmaceutical (8.42% YoY growth) and Cipla (13.28% YoY growth) show robust profitability and low debt levels.
• The target company is financially distressed with a debt-to-equity ratio of 0 and negative ROE, indicating poor returns on equity.

Top Performers

Sun Pharmaceutical Industries Ltd.

Strong revenue growth and profitability with a PE ratio of 87.59 and a low debt-equity ratio.

Cipla Ltd.

Solid revenue growth of 13.28% YoY and a low PE ratio of 23.73 with high ROA.

Dr. Reddy's Laboratories Ltd.

Consistent growth and profitability metrics with a PE of 15.50 and strong returns on equity.